Inappropriate implementation of guideline-recommended use of ACE inhibitors after acute myocardial infarction in patients with left ventricular dysfunction;ACE-inhibition bei myokardinfarktpatienten mit eingeschränkter ventrikelfunktion: Umsetzung von therapiestandards in bevölkerungsstichproben

Zeitschrift fur Kardiologie

Volumn 90, Issue 2, 2001, Pages 104-110

  Fischer, M ^a   Bassler A ^a   Hengstenberg, C ^a   Holmer, S ^a   Mayer, B ^a   Lowel H ^b   Riegger, G ^a   Klein, G ^c   Schunkert, Heribert ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c Klinik Hohenried   (Germany)

Author keywords

ACE inhibitors; Drug use; Myocardial infarction; Secondary prevention

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DISEASE COURSE; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART REHABILITATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PRESCRIPTION;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CAPTOPRIL; CLINICAL TRIALS; CONFIDENCE INTERVALS; ECHOCARDIOGRAPHY; ENALAPRIL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PRACTICE GUIDELINES; QUESTIONNAIRES; RAMIPRIL; REGISTRIES; SAMPLING STUDIES; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0035071761     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003920170196     Document Type: Article

References (25)

1. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
2. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial
3. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
4. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
5. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy
6. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction
7. Secondary prevention in coronary heart disease: Baseline survey of provision in general practice
8. Use of secondary prophylaxis against myocardial infarction in the north of England
9. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events)
10. Determinants of appropriate use of angiotensin converting enzyme inhibitor after acute myocardial infarction in persons
11. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials
12. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients
13. The treatment of heart failure
14. Guidelines for the evaluation and management of heart failure
15. Leitlinien zur therapie der chronischen herzinsuffizienz
16. Indikation von ACE-hemmern in der postinfarktphase
17. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
18. Differential effects of antihypertensive drugs on neurohormonal activation: Insights from a population-based sample
19. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure
20. Feedback regulation of angiotensin converting enzyme activity and mRNA levels by angiotensin II
21. Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?
22. The multilevel compliance challenge: Recommendations for a call to action. A statement for healthcare professionals
23. Prevention Conference V Beyond secondary prevention: Identifying the high-risk patient for primary prevention. Executive summary
24. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology
25. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population